Graph AI, a California-based artificial intelligence firm focused on drug safety and pharmacovigilance, has raised $3 million in seed funding led by Bessemer Venture Partners.
The startup plans to use the capital to scale product development, expand its engineering team, and accelerate adoption of its automation platform among global pharmaceutical companies.
Founded in 2024 by Raghav Parvataraju, Vijay Ponukumati, Mohan Konyala, and Ashutosh Bordekar, Graph AI aims to modernise how drugmakers detect and report adverse drug events, an area heavily dependent on manual, labor-intensive processes. The founders previously held roles at LTI Mindtree, Infosys, ServiceNow, Google, and Cisco.
The company’s flagship platform, Graph Safety, uses context-aware AI to automate tasks such as case processing, signal detection, and regulatory reporting, while keeping humans involved for critical oversight steps.
Pharmacovigilance, mandated by regulators globally, requires drugmakers to continuously monitor and report potential side effects from clinical trials through post-market use.
Traditionally, the work is outsourced to large service firms that rely on teams of pharmacology graduates to comb through unstructured data such as medical reports, call transcripts, and legal filings. Graph AI says its technology can make this process up to 90% faster and 70% more efficient, reducing compliance delays and operational costs.
“Life sciences companies still struggle with outdated, fragmented systems that slow decision-making,” the founders said in a joint statement. “We’re building an AI-native safety platform that integrates context, compliance, and intelligence to help organizations achieve safer outcomes and stronger regulatory confidence.”
Bessemer’s India partner and COO, Nithin Kaimal, said, the firm’s investment reflects confidence in AI’s potential to “shift delivery from labor arbitrage to intelligence arbitrage,” transforming traditional service-heavy models into scalable, technology-led systems.
Graph AI has already deployed its platform with enterprise customers and is building a pipeline spanning over 7,000 marketed drugs.
